This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Demonstration of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study


Kennelly, S. P., Abdullah, L., Paris, D., Parish, J., Mathura, V., Mullan, M., Crawford, F., Lawlor, B. A., Kenny, R. A.


International Journal Of Geriatric Psychiatry, Volume: 26, No.: 10, Pages.: 1038-1045

Year of Publication



Background: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer’s disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the further exaggeration of a drop in BP.; Objective: The aim of this study was to investigate the safety and tolerability of nilvadipine in AD patients.; Methods: AD patients in the intervention group (n = 56) received nilvadipine 8  mg daily over 6-weeks, compared to the control group (n = 30) who received no intervention. Differences in systolic (SBP) and diastolic (DBP) blood pressure, before and after intervention, was assessed using automated sphygmomanometer readings and ambulatory BP monitors (ABP), and change in OH using a finometer. Reporting of adverse events was monitored throughout the study.; Results: There was a significant reduction in the SBP of treated patients compared to non-treated patients but no significant change in DBP. Individuals with higher initial blood pressure (BP) had greater reduction in BP but individuals with normal BP did not experience much change in their BP. While OH was present in 84% of the patients, there was no further drop in BP recorded on active stand studies. There were no significant differences in adverse event reporting between groups.; Conclusion: Nilvadipine was well tolerated by patients with AD. This study supports further investigation of its efficacy as a potential treatment for AD.; Copyright © 2010 John Wiley & Sons, Ltd.

Bibtex Citation

@article{Kennelly_2010, doi = {10.1002/gps.2638}, url = {}, year = 2010, month = {oct}, publisher = {Wiley-Blackwell}, volume = {26}, number = {10}, pages = {1038--1045}, author = {S. P. Kennelly and L. Abdullah and D. Paris and J. Parish and V. Mathura and M. Mullan and F. Crawford and B. A. Lawlor and R. A. Kenny}, title = {Demonstration of safety in Alzheimer{textquotesingle}s patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study}, journal = {Int. J. Geriat. Psychiatry} }


adverse, adverse effects, aged, aged, 80 and over, alzheimer disease, analogs derivatives, antihypertensive, antihypertensive agents, blood, blood pressure, drug effects, drug therapy, events, female, humans, male, middle aged, nifedipine, nilvadipine, pressure

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Non randomised controlled trial

Type of Outcomes

Other, Physical Health

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions